Suzuken Co Ltd
TSE:9987
Suzuken Co Ltd
TSE:9987
Price:
4 656 JPY
3.4%
Updated:
Apr 26, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
2.6
Current
2.7
Median
12.3
Industry
Lower
than median
Lower
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=2.6
Enterprise Value
/
111.2B
EBITDA
43.6B
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| JP |
|
Suzuken Co Ltd
TSE:9987
|
353.3B JPY | 2.6 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
70.7B USD | 16.4 | |
| US |
|
Cencora Inc
NYSE:COR
|
47.8B USD | 13.1 | |
| US |
|
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 11.3 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
25.3B USD | 8.9 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.4B USD | 11.9 | |
| KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 59.9 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
67.3B HKD | 1.7 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
57.3B CNY | 15.5 | |
| IT |
|
Amplifon SpA
MIL:AMP
|
7.1B EUR | 14.8 | |
| CN |
S
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
50.8B CNY | 8 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
2.8
2-Years Forward
EV/EBITDA
2.7
3-Years Forward
EV/EBITDA
2.4
You don't have any saved screeners yet
